Product Details
Alternative Name: | ABCB1, CD243, P-glycoprotein 1 |
|
Clone: | MRK16 |
|
Host: | Mouse |
|
Isotype: | IgG2a |
|
Immunogen: | Adriamycin-resistant human myelogenous leukemia K-562/ADM cells. |
|
UniProt ID: | P08183 |
|
Species reactivity: | Human
|
|
Specificity: | Recognizes an external epitope of human P-glycoprotein. Also recognizes P-glycoprotein of human cortical adenomas. |
|
Crossreactivity: | Does not cross-react with mouse P-glycoprotein. |
|
Applications: | Flow Cytometry, IHC (FS), IP, FUNC
|
|
Recommended Dilutions/Conditions: | Flow Cytometry: For 5x105 pelleted cells use 50µl of 10-100µg/ml. Immunohistochemistry (frozen sections): 0.1-10µg/ml. Use mild fixation treatment such as 4% paraformaldehyde. Do not use acetone, paraffin, methanol or ethanol as a fixative. Iodine labelling can also be performed on MRK16. Immunoprecipitation: 25-50µg/ml Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Application Notes: | Functional Application: Inhibits P-glycoprotein function. Not recommended for Western blot (epitope recognized by this antibody may be lost in the presence of protein denaturing agents such as SDS). |
|
Purity Detail: | Protein A affinity purified. |
|
Formulation: | Liquid. In PBS containing 1% BSA and 0.1% sodium azide. |
|
Handling: | Avoid freeze/thaw cycles. |
|
Shipping: | Shipped on Blue Ice |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Conformational heterogeneity of P-glycoprotein: K. Goda, et al.; Cancer Detect. Prev.
24, 415 (2000),
Abstract;
Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system: J.J. Gribar, et al.; J. Membr. Biol.
173, 203 (2000),
Abstract;
Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein: F. Ushigome, et al.; Eur. J. Pharmacol.
408, 1 (2000),
Abstract;
Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules: H. Dassow, et al.; Int. J. Clin. Pharmacol. Ther.
38, 209 (2000),
Abstract;
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier: V.V. Rao, et al.; PNAS
96, 3900 (1999),
Abstract;
Full Text
Discordance of P-glycoprotein expression and function in acute leukemia: B. De Moerloose, et al.; Adv. Exp. Med. Biol.
457, 107 (1999),
Abstract;
P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833: M. Egashira, et al.; Blood
93, 599 (1999),
Abstract;
Full Text
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network: S. Huet, et al.; Cytometry
34, 248 (1998),
Abstract;
The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis: M.J. Smyth, et al.; PNAS
95, 7024 (1998),
Abstract;
Full Text
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res.
56, 3010 (1996),
Abstract;
In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody: A.M. Scott, et al.; Nucl. Med. Biol.
22, 497 (1995),
Abstract;
Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1: T. Hoof, et al.; J. Biol. Chem.
269, 20575 (1994),
Abstract;
Full Text
Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein: A.H. Schinkel, et al.; Int. J. Cancer
55, 478 (1993),
Abstract;
Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators: J. Hunter, et al.; J. Biol. Chem.
268, 14991 (1993),
Abstract;
Full Text
Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model: T. Iwahashi, et al.; Cancer Res.
53, 5475 (1993),
Abstract;
Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody: E. Georges, et al.; J. Biol. Chem.
268, 1792 (1993),
Abstract;
Full Text
Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin: C.H. Evans & P.D. Baker; Cancer Res.
52, 5893 (1992),
Abstract;
Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma: Y. Mizuno, et al.; Eur. J. Pediatr.
150, 416 (1991),
Abstract;
Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers: D. Schlaifer, et al.; Br. J. Cancer
62, 177 (1990),
Abstract;
Further characterization of the human adrenal-derived P-glycoprotein recognized by monoclonal antibody MRK 16 reacting with only human P-glycoprotein: I. Sugawara, et al.; Jpn. J. Cancer Res.
80, 1199 (1989),
Abstract;
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16: Y. Ishida, et al.; Jpn. J. Cancer Res.
80, 1006 (1989),
Abstract;
Mechanisms of multidrug resistance and implications for therapy: T. Tsuruo; Jpn. J. Cancer Res.
79, 285 (1988),
Abstract;
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells: D.J. FitzGerald, et al.; PNAS
84, 4288 (1987),
Abstract;
Functional role for the 170- to 180-kDa glycoprotein specific to drug- resistant tumor cells as revealed by monoclonal antibodies: H. Hamada and T. Tsuruo; PNAS
83, 7785 (1986),
Abstract;